A Phase 2, Randomized, Prospective, Double-masked, Vehicle-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Nexagon in Subjects With Persistent Corneal Epithelial Defects (PED) From Chemical Burn Injuries.

Trial Profile

A Phase 2, Randomized, Prospective, Double-masked, Vehicle-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Nexagon in Subjects With Persistent Corneal Epithelial Defects (PED) From Chemical Burn Injuries.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2014

At a glance

  • Drugs CODA 001 (Primary)
  • Indications Wounds
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors CoDa Therapeutics Inc
  • Most Recent Events

    • 08 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top